GlassScriptPhysician profile
Lee K Dionne
NPI 1104472679
$6,998.20
in general payments reported to CMS, 2019-2025
23 companies · $1,921 in 2025
The $1,921 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $812 · 2023: $1,920 · 2024: $1,909 · 2025: $1,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,217 · Consulting Fee: $368 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,217.02 |
| Consulting Fee | $368.00 |
| Education | $165.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,420.07 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,086.84 | 2023-2025 | Sotyktu, Sprycel |
| Galderma Laboratories, L.P. | $633.08 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $479.33 | 2021-2025 | |
| Ucb, INC. | $466.61 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $450.89 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $383.13 | 2021-2024 | Olumiant, Taltz, Ebglyss |
| Janssen Biotech, INC. | $289.05 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $286.03 | 2021-2025 | Dupixent |
| Amgen INC. | $189.84 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $177.98 | 2022-2025 | |
| Pfizer INC. | $155.25 | 2023-2025 | |
| Organon LLC | $150.00 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $139.83 | 2021-2023 | Ilumya, Winlevi, Blu-U |
| Leo Pharma INC. | $135.04 | 2021-2025 | Anzupgo, Adbry |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $121.13 | 2022-2024 | Opzelura |
| Revance Therapeutics, INC. | $92.04 | 2024 | Daxxify |
| Journey Medical Corporation | $86.55 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $72.44 | 2023-2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.18 | 2024-2025 | Cabtreo, Siliq |
| Almirall LLC | $61.04 | 2022-2023 | Seysara |
| Dermavant Sciences, INC. | $34.17 | 2023-2024 | Vtama |
| Botanix Sb INC | $20.68 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Dionne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.